Skip to content

Price / book at other companies

Incyte logo
IncyteINCY
3.3×+0.1×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
1.7×-0.6×
UroGen Pharma logo
UroGen PharmaURGN
20.5×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
3.1×0.0×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
49.5×+44.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+1.3×

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.79B+318%
Enterprise value$1.71B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s price / book?
Tyra Biosciences, Inc. (TYRA) reported price / book of 5.3× in Q1 2026.
How has Tyra Biosciences, Inc.'s price / book changed year-over-year?
Tyra Biosciences, Inc.'s price / book increased by 248.8% year-over-year, from 1.5× to 5.3×.
What is the long-term trend for Tyra Biosciences, Inc.'s price / book?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s price / book has grown at a 29.3% compound annual growth rate (CAGR), from 1.9× to 5.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.